人乳头瘤病毒基因型对全球浸润性宫颈癌的因果归因:全球文献的系统分析
该系统综述纳入1174项研究、111902例HPV阳性浸润性宫颈癌和2755734例正常宫颈细胞学,通过 logistic 回归估计各HPV基因型的OR并判定因果关系。17种HPV基因型被判定为浸润性宫颈癌的因果基因型,HPV16全球归因分数最高(61.7%),其次为HPV18(15.3%)。
要点
- 17种HPV基因型被判定为浸润性宫颈癌的因果基因型。
- HPV16全球归因分数最高(61.7%),HPV18次之(15.3%)。
- HPV16/18及HPV16/18/31/33/45/52/58合并归因分数在非洲最低,在中亚、西亚和南亚最高。
核心结论
- 该研究提供了HPV疫苗接种影响之前全球浸润性宫颈癌中各HPV基因型归因分数的全面图景,这些数据可用于指导针对特定HPV基因型的疫苗接种和筛查策略,以减轻浸润性宫颈癌负担。
研究设计与样本
- 系统综述检索PubMed、Embase、Scopus和Web of Science截至2024年2月29日的文献,无语言限制,检索词为「cervix」和「HPV」。
- 共纳入1174项报告浸润性宫颈癌或正常宫颈细胞学中HPV基因型特异性患病率的研究,包括111902例HPV阳性浸润性宫颈癌和2755734例正常宫颈细胞学。
- 采用logistic回归模型比较HPV阳性浸润性宫颈癌与正常宫颈细胞学之间HPV基因型特异性患病率以估计OR,并调整地区、论文发表年份和HPV引物或检测方法。
主要发现
- 17种HPV基因型被判定为浸润性宫颈癌的因果基因型,OR范围从HPV16的48.3(95%CI 45.7-50.9)到HPV51的1.4(95%CI 1.2-1.7)。
- 全球归因分数:HPV16为61.7%,HPV18为15.3%,HPV45为4.8%,HPV33为3.8%,HPV58为3.5%,HPV31为2.8%,HPV52为2.8%。
- 其余因果基因型(HPV35、59、39、56、51、68、73、26、69和82)的合并全球归因分数为5.3%。
- HPV16和18的归因分数在非洲最低(71.9%),在中亚、西亚和南亚最高(83.2%);HPV16、18、31、33、45、52和58合并归因分数在非洲最低(92.1%),在中亚、西亚和南亚最高(95.9%)。
- HPV35在非洲的归因分数(3.6%)高于其他地区(0.6%-1.6%)。
关键数值与推荐
- OR的95%CI下限大于1.0的HPV基因型被判定为浸润性宫颈癌的因果基因型。
- 区域基因型特异性归因分数计算为区域HPV在浸润性宫颈癌中的患病率乘以(1 - [1 / OR]),并按比例调整至总和100%。
- 全球归因分数由区域归因分数按2022年区域浸润性宫颈癌病例数(GLOBOCAN)加权计算。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Understanding the proportion of invasive cervical cancer (ICC) caused by different human papillomavirus (HPV) genotypes can inform primary (ie, vaccination) and secondary (ie, screening) prevention efforts that target specific HPV genotypes. However, using the global literature to estimate population attributable fractions (AFs) requires a methodological framework to address HPV genotype-specific causality from aggregated data. We aimed to estimate the proportion of ICC caused by different HPV genotypes at the global, regional, and national level. METHODS: This systematic review identified studies reporting HPV genotype-specific prevalence in ICC or people with normal cervical cytology. We searched PubMed, Embase, Scopus, and Web of Science up to Feb 29, 2024, using the search terms "cervix" and "HPV", with no language restrictions. Odds ratios (ORs) were estimated by comparing HPV genotype-specific prevalence between HPV-positive ICC and normal cervical cytology with logistic regression models, adjusting for region, year of paper publication, and HPV primer or test. HPV genotypes with a lower bound to the 95% CI of the OR greater than 1·0 were judged as causal to ICC. Corresponding regional genotype-specific AFs were calculated as regional HPV prevalence in ICC multiplied by (1 - [1 / OR]) and were proportionally adjusted to total 100%. Global AFs were calculated from regional AFs weighted by number of regional ICC cases in 2022 (GLOBOCAN). FINDINGS: The systematic review identified 1174 studies with 111 902 cases of HPV-positive ICC and 2 755 734 of normal cervical cytology. 17 HPV genotypes were considered causal to ICC, with ORs ranging widely from 48·3 (95% CI 45·7-50·9) for HPV16 to 1·4 (1·2-1·7) for HPV51. HPV16 had the highest global AF (61·7%), followed by HPV18 (15·3%), HPV45 (4·8%), HPV33 (3·8%), HPV58 (3·5%), HPV31 (2·8%), and HPV52 (2·8%). Remaining causal genotypes (HPV35, 59, 39, 56, 51, 68, 73, 26, 69, and 82) had a combined global AF of 5·3%. AFs for HPV16 and 18 and HPV16, 18, 31, 33, 45, 52, and 58 combined were lowest in Africa (71·9% and 92·1%, respectively) and highest in central, western, and southern Asia (83·2% and 95·9%, respectively). HPV35 had a higher AF in Africa (3·6%) than other regions (0·6-1·6%). INTERPRETATION: This study provides a comprehensive global picture of HPV genotype-specific AFs in ICC, before the influence of HPV vaccination. These data can inform HPV genotype-specific vaccination and screening strategies to reduce the burden of ICC. FUNDING: EU Horizon 2020 Research and Innovation Programme.
引用
- Wei F, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024. PMID: 39097395. doi:10.1016/S0140-6736(24)01097-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。